ATE208209T1 - Die kombination des wachstumhormones und des insulinähnlichen wachstumsfaktors-i zur behandlung von kongestivem herzversagen - Google Patents

Die kombination des wachstumhormones und des insulinähnlichen wachstumsfaktors-i zur behandlung von kongestivem herzversagen

Info

Publication number
ATE208209T1
ATE208209T1 AT95914882T AT95914882T ATE208209T1 AT E208209 T1 ATE208209 T1 AT E208209T1 AT 95914882 T AT95914882 T AT 95914882T AT 95914882 T AT95914882 T AT 95914882T AT E208209 T1 ATE208209 T1 AT E208209T1
Authority
AT
Austria
Prior art keywords
combination
mammal
heart failure
congestive heart
insulin
Prior art date
Application number
AT95914882T
Other languages
English (en)
Inventor
Ross G Clark
Hongkui Jin
Nicholas F Paoni
Renhui Yang
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/284,859 external-priority patent/US5661122A/en
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE208209T1 publication Critical patent/ATE208209T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
AT95914882T 1994-04-15 1995-03-30 Die kombination des wachstumhormones und des insulinähnlichen wachstumsfaktors-i zur behandlung von kongestivem herzversagen ATE208209T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22792394A 1994-04-15 1994-04-15
US08/284,859 US5661122A (en) 1994-04-15 1994-08-02 Treatment of congestive heart failure
US08/333,909 US5610134A (en) 1994-04-15 1994-11-03 Treatment of congestive heart failure
PCT/US1995/003755 WO1995028174A1 (en) 1994-04-15 1995-03-30 The combination of growth hormone and insulin-like growth factor, for treating congestive heart failure

Publications (1)

Publication Number Publication Date
ATE208209T1 true ATE208209T1 (de) 2001-11-15

Family

ID=27397790

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95914882T ATE208209T1 (de) 1994-04-15 1995-03-30 Die kombination des wachstumhormones und des insulinähnlichen wachstumsfaktors-i zur behandlung von kongestivem herzversagen

Country Status (12)

Country Link
US (1) US5610134A (de)
EP (1) EP0755265B1 (de)
JP (1) JP3473623B2 (de)
AT (1) ATE208209T1 (de)
AU (1) AU691273B2 (de)
CA (1) CA2185998C (de)
DE (1) DE69523747T2 (de)
DK (1) DK0755265T3 (de)
ES (1) ES2167427T3 (de)
LV (1) LV12966B (de)
PT (1) PT755265E (de)
WO (1) WO1995028174A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3182307B2 (ja) * 1994-12-27 2001-07-03 株式会社荏原製作所 全周流型ポンプ
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
WO1997034604A1 (en) * 1996-03-21 1997-09-25 Merck & Co., Inc. 4-spiroindoline piperidines promote release of growth hormone
US6306826B1 (en) 1997-06-04 2001-10-23 The Regents Of The University Of California Treatment of heart failure with growth hormone
US6015384A (en) * 1998-08-31 2000-01-18 Acuson Corporation Ultrasonic system and method for tissue viability imaging
SE9901634D0 (sv) * 1999-05-05 1999-05-05 Sahltech Ab Treatment of myocardial infarction with a substance related to the growth hormone axis
NZ516507A (en) * 1999-07-12 2004-02-27 Grandis Biotech Gmbh Growth hormone formulations that are resistant to crystallisation
CA2378179A1 (en) * 1999-07-12 2001-01-18 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
EP1255829B1 (de) 2000-02-11 2009-08-19 Genentech, Inc. Inhibitor des hepatozytwachstumsfaktoraktivators und dessen verwendung zur modulation von angiogenese und herzvaskularisierung
FR2805051B1 (fr) * 2000-02-14 2002-12-06 Geophysique Cie Gle Methode de surveillance sismique d'une zone souterraine par utilisation simultanee de plusieurs sources vibrosismiques
CA2648051A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
DK2042597T3 (da) 2000-06-23 2014-08-11 Genentech Inc Sammensætninger og fremgangsmåder til diagnose og behandling af sygdomme, der involverer angiogenese
RU2298415C2 (ru) * 2000-07-11 2007-05-10 Сандоз Аг Композиции, включающие гормон роста
US20020061587A1 (en) 2000-07-31 2002-05-23 Piero Anversa Methods and compositions for the repair and/or regeneration of damaged myocardium
US7862810B2 (en) 2000-07-31 2011-01-04 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US7547674B2 (en) * 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US20030224984A1 (en) * 2001-06-20 2003-12-04 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US6607517B1 (en) 2001-08-24 2003-08-19 Radiant Medical, Inc. Method of inotropic treatment of heart disease using hypothermia
DK1581251T3 (da) 2002-12-31 2016-06-27 Althea Tech Inc Krystaller af humant væksthormon og fremgangsmåder til fremstilling deraf
EP1841443A4 (de) * 2005-01-11 2012-05-02 Heart Failure Technologies Inc Verfahren und system zur behandlung von herzfehlern
US8119123B2 (en) 2006-02-16 2012-02-21 New York Medical College Compositions comprising vascular and myocyte progenitor cells and methods of their use
WO2009062143A2 (en) 2007-11-09 2009-05-14 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium using cytokines and variants thereof
AU2008334036B2 (en) 2007-11-30 2014-05-29 New York Medical College Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells
US8512696B2 (en) 2007-11-30 2013-08-20 Autologous, Llc Methods of isolating non-senescent cardiac stem cells and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
ES2084190T3 (es) * 1990-10-25 1996-05-01 Genentech Inc Utilizacion de agentes protectores contra especies de oxigeno reactivas.
SE9100099D0 (sv) * 1991-01-11 1991-01-11 Kabi Pharmacia Ab Use of growth factor
SE9101840L (sv) * 1991-06-14 1992-12-15 Kabi Pharmacia Ny medicinsk anvaendning
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
AU2147192A (en) * 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone

Also Published As

Publication number Publication date
DK0755265T3 (da) 2002-03-04
JP3473623B2 (ja) 2003-12-08
LV12966B (en) 2003-05-20
DE69523747T2 (de) 2002-08-01
US5610134A (en) 1997-03-11
EP0755265B1 (de) 2001-11-07
AU691273B2 (en) 1998-05-14
EP0755265A1 (de) 1997-01-29
ES2167427T3 (es) 2002-05-16
DE69523747D1 (de) 2001-12-13
CA2185998A1 (en) 1995-10-26
AU2195695A (en) 1995-11-10
PT755265E (pt) 2002-04-29
JPH09512008A (ja) 1997-12-02
WO1995028174A1 (en) 1995-10-26
HK1003418A1 (en) 1998-10-30
CA2185998C (en) 2011-02-22

Similar Documents

Publication Publication Date Title
ATE208209T1 (de) Die kombination des wachstumhormones und des insulinähnlichen wachstumsfaktors-i zur behandlung von kongestivem herzversagen
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
DE69327402D1 (de) Vorbeugung und behandlung der peripheren neuropathie
ATE141799T1 (de) Die kombination des wachshormons und des insulin- ähnlichen wachstumsfaktors-i stimuliert das wachstum
DE69230789D1 (de) Methoden zur behandlung von durch den tumor nekrose faktor ausgelösten krankheiten
PL338705A1 (en) Application of gaba analogues in preventing and treating gastrointestinal diseases
DE69807349D1 (de) Thyroxin-analoga ohne bedeutende hormonale wirkung zur behandlung von bösartigen tumoren
ATE422357T1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
ATE215835T1 (de) Verfahren zur systemischen behandlung katabolischer zustände und systemischer gewebeschädigung
DE69838509D1 (de) Verwendung von rekombinanten menschlichen uteroglobin zur behandlung von fibrotischen krankheitszuständen
ATE201598T1 (de) Verwendung von moxonidin zur behandlung neuropathischer schmerzen
DE69808131D1 (de) Verfahren zur vorbeugung und behandlung des myokardialen stunnings
ATE121296T1 (de) Igf-i zur behandlung von nebeneffekten der steroidtherapie.
ATE228006T1 (de) Verwendung von vip zur erstellung eines medikamentes zur behandlung des endotoxischen schocks in säugetieren
ATE212845T1 (de) Verwendung von cytochrome - p 450 - inhibitoren zur hemmung des stoffwechsels von stickstoffsubstituierten acridinen
CA2136953A1 (en) A method for using lipoprotein associated coagulation inhibitor to treat sepsis
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
MX9604803A (es) Combinacion de hormona del crecimiento y factor de crecimiento similar a insulina para el tratamiento del fallo cardiaco congestivo.
DE3382012D1 (de) Zusammensetzung zur behandlung von laeuseplagen.
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
DE60028750D1 (de) Verwendung von tagatose zur verbesserung wichtiger blutfaktoren
RU94042315A (ru) Способ лечения язвенной болезни желудка и двенадцатиперстной кишки
DE50009220D1 (de) Verwendung von moxonidin zur behandlung nach herzinfarkt
RU97109107A (ru) Способ лечения гнойных ран
SU1097329A1 (ru) Способ лечени беременных с иммунным конфликтом

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification